Cannabis Report
Home > Boards > US OTC > Computers - Hardware >

GeoVax Labs Inc. (GOVX)

Add GOVX Price Alert      Hide Sticky   Hide Intro
Moderator: dolse
Search This Board: 
Last Post: 8/15/2018 2:15:05 PM - Followers: 153 - Board type: Free - Posts Today: 1


GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using our novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology.

Our proprietary vaccine technology has been developed through multi-year collaborations with the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC), and Emory University.  Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.

Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses (Ebola, Sudan, Marburg and Lassa) and Zika virus. We also have initiated programs to develop a vaccine to treat chronic Hepatitis B infection and to apply our MVA-VLP vector technology to cancer immunotherapy (immuno-oncology). We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases and we intend to pursue expansion of our product.

Our hemorrhagic fever vaccine program was initiated during 2014 in response to the Ebola epidemic in western Africa and with the goal of developing second generation monovalent and multivalent vaccines capable of preventing or containing future outbreaks of major hemorrhagic fever viruses indigenous to Africa. Our initial preclinical studies in rodents and nonhuman primates for our first vaccine candidate (Ebola-Zaire virus) have shown 100% protection against death after a single dose.

Our most advanced vaccines under development are designed to function against the clade B subtype of the HIV virus that is prevalent in the Americas and Western Europe. Our preventive clade B HIV vaccine has successfully completed Phase 2a human clinical testing has entered a follow-on clinical trial in 2017. Our clade B vaccine has shown outstanding safety and excellent, highly reproducible immunogenicity. We are extending our HIV vaccine effort to the most common virus subtype affecting the developing world, clade C. We also are investigating our HIV vaccines for their potential to contribute to combination therapies leading to a cure for HIV infections.
Our vaccine technology was developed in collaboration with researchers at Emory University, the NIH, and the CDC. The technology is exclusively licensed to us from Emory University. We also have nonexclusive licenses to certain patents owned by the NIH. Our hemorrhagic fever vaccines have been developed with technology licensed from, and in collaboration with, the NIH. Our immuno-oncology program is being developed pursuant to a research collaboration with the University of Pittsburgh. Our Zika vaccine program is in collaboration with University of Georgia and the CDC. Our HBV therapeutic program is in collaboration with Georgia State University and our malaria vaccine is being developed in collaboration with Burnet Institute in Australia.

Our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants awarded directly to us, in kind support in terms of animal experiments, as well as indirect support for the conduct of our human clinical trials. All of the human clinical trials of our preventative vaccines to date have been conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).


We know our work could affect the lives of millions worldwide, and we invite you to join our effort.



                                                                                  Technology Pipeline

Pipeline 03 16 2017 Final                                                                                                                                         



 Robert McNally, CEO of GeoVax Labs Inc.,

Watch This Informative 3 Minute Clip Presented By GeoVax President and CEO Robert McNally Giving An Overview Of The Company
#2 and #22  most influential vaccine scientist recently joined GOVX 

2016 Annual Letter to Shareholders 

We are committed to providing our shareholders with accessible, complete information about our company. Within this section of the website, you will find comprehensive stock information, corporate data and progress reports.

Investment Highlights

Recent entry into high-profile Zika vaccine space with multiple collaborators
Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and distinct advantages vs existing vaccines
Multiple targets in the Cancer Immunotherapy space
Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe)

Novel vaccine technology developed at Emory University, NIH and CDC
Proven vaccine protection in HIV and Ebola animal models
Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date
Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
Strong global patent position with additional manufacturing technical know-how barriers to entry

Global Vaccine Market Surging to More Than $70 Billion by 2024 thats 25x the size of medical marijuana industry of 3 Billion by 2020. 

Sabby Management own 5,518,000 shares 10%+ a major increase from 2016 to 2017
Emory University owns 10% 


Researcher: GOVX  Zika vaccine could be ready in two years



Zika vaccine developer names new chief scientific officer

                                                                                                        Jan 3, 2017, 10:51am EST Updated Jan 4, 2017, 11:59pm EST


Get Atlanta Newsletters and Aler
Morning Edition >> Afternoon Edit

Enter your email address

SignA Smyrna-based developer of vac                                                       A Smyrna-based developer of vaccines against Zika, Ebola, HIV and other infectious diseases has named a new chief scientific officer.

Farshad Guirakhoo was promoted to the C-suite role at GeoVax Labs Inc. from senior vice president of research and development, his title upon joining the company in 2015. The promotion was effective Jan. 1.

Farshad Guirakhoo

His predecessor as CSO, company co-founder Harriet L. Robinson, will remain as chief scientific officer emeritus, the company said in a statement.

"For the past year, Farshad has been a driving force behind the growth of our vaccine development pipeline, and we are pleased to expand his role at this critical time for our company," GeoVax President and CEO Robert T. McNallysaid in the statement. "In the role of Chief Scientific Officer, Dr. Guirakhoo will lead the scientific advancement of GeoVax's technology pipeline as the Company identifies and pursues new opportunities to address significant medical needs."

Robinson will continue to direct the company's HIV vaccine program and to serve as principal investigator on National Institutes of Health grants to GeoVax, McNally said. Robinson will also continue to serve as a member of the GeoVax Board of Directors.

Before joining GeoVax in 2015, Guirakhoo served in senior management and scientific roles with biotechnology companies included Vaxess Technologies, Hookipa Biotech, Sanofi Pasteur, Acambis Inc. and OraVax Inc. He earned his Ph.D. in virology at the Medical University of Vienna in Vienna, Austria, and he holds a M.Sc. degree in genetics and a B.Sc. degree in biology. His post-doctoral training included a stint at the Centers for Disease Control and Prevention'sDivision of Vector-Borne Infectious Diseases in Fort Collins, Colo. Guirakhoo has filed over 90 patent applications in his scientific career, according to the statement, and was instrumental in the development and commercialization of the Imojev Japanese encephalitis virus vaccine and the Dengvaxia vaccine for Dengue virus.

GeoVax Labs Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases. Its development programs are focused on vaccines against HIV, Zika, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa).

In February 2016, The University of Georgia and GeoVax announced a collaboration to develop and test a possible Zika virus vaccine. 

                                                                                                 Our Technology


Vaccines typically contain agents (antigens) that resemble disease-causing microorganisms. Traditional vaccines are often made from weakened or killed forms of the virus or from its surface proteins. Many newer vaccines use recombinant DNA (deoxyribonucleic acid) technology to generate vaccine antigens in bacteria or cultured cells from specific portions of the DNA sequence of the target pathogen. The generated antigens are then purified and formulated for use in a vaccine. The most successful of these purified antigens have been non-infectious virus-like particles (VLPs) as exemplified by vaccines for hepatitis B (Merck's Recombivax® and GSK's Engerix®) and Papilloma viruses (GSK's Cervarix®, and Merck's Gardasil®). Our approach uses recombinant DNA or recombinant viruses to produce VLPs in the person being vaccinated. In human clinical trials of our HIV vaccines, we have demonstrated that our VLPs, expressed in the cells of the person being vaccinated, are safe, yet elicit both strong and durable humoral and cellular immune response.

VLPs train the body's immune system to recognize and kill the authentic virus should it appear. VLPs also train the immune system to recognize and kill infected cells to control infection and reduce the length and severity of disease. One of the biggest challenges with VLP-based vaccines is to design the vaccines in such a way that the VLPs will be recognized by the immune system in the same way as the authentic virus would be. When VLPs for enveloped viruses like HIV, Ebola, Marburg  or Lassa fever are produced in vivo, they include not only the protein antigens, but also an envelope consisting of membranes from the vaccinated individual's cells. In this way, they are highly similar to the virus generated in a person's body during a natural infection. VLPs produced externally, by contrast, have no envelope; or, envelopes from the cultured cells (typically hamster or insect cells) used to produce them. We believe our technology provides distinct advantages by producing VLPs that more closely resemble the authentic virus, which in turn, allows the body's immune system to more readily recognize the authentic virus. By producing VLPs in vivo, we avoid potential purification issues associated with in vitro production of VLPs.

Ebola VLP                 HIV VLP

                    Ebola VLPs                                                                               HIV VLPs

Electron micrographs showing the VLPs elicited by GeoVax vaccines from human cells. Note that the Ebola VLPs on the left self-assemble into the rod-like shape of the authentic Ebola virus, while the HIV VLPs shown on the right take on the spherical shape of the authentic HIV virus. While below the resolution of these micrographs, both types of VLPs display what we believe to be the native form of their respective viral envelope glycoproteins which we believe is key to generating an effective immune humoral response.

Our MVA-VLP vector affords other unique advantages:

Safety: GeoVax/NIAID rMVA HIV vaccines have demonstrated outstanding safety in human clinical trials. Safety for MVA has been shown in more than 120,000 subjects in Europe, including immunocompromised individuals during the initial development of MVA and more recently with the development of MVA as a safer vaccine against smallpox.

Durability: GeoVax/NIAID rMVA technology raises highly durable vaccine responses, the most durable in the field of vectored HIV vaccines. We hypothesize that elicitation of durable vaccine responses is conferred on responding B cells by the vaccinia parent of MVA, which raises highly durable responses for smallpox.

Limited pre-existing immunity to vector: Following the eradication of smallpox in 1980, smallpox vaccinations subsequently ended, leaving all but those born before 1980 and selected populations (such as vaccinated laboratory workers, first responders) unvaccinated and without pre-existing immunity.

No need for adjuvants: MVA stimulates strong innate immune responses and does not require the use of adjuvants.

Thermal stability: MVA is stable in both liquid and lyophilized formats (> 6 years of storage).

Genetic stability and manufacturability: If appropriately engineered, MVA is genetically stable and can reliably be manufactured in either the established Chick Embryo Fibroblast cell substrate, or novel continuous cell lines that support scalability as well as greater process consistency and efficiency.

GOVX Zika Quicklinks: Breaking News

March ,2017 
March, 2017 
March, 2017 
Febuary , 2017
January, 2017
January, 2017

October, 2016        GeoVax to Present at Upcoming Scientific Conferences on its Hemorrhagic Fever and Zika Vaccine Programs
June, 2016            GeoVax Discusses Zika Vaccine Development at American Society for Virology’s 35th Annual Meeting
June, 2016            GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting
May, 2016             GeoVax Presents at Zika Virus Scientific Conference
April, 2016            GeoVax Provides Update on Zika Vaccine Program
March, 2016         GeoVax Extends Research Collaborations on Zika Vaccine
March, 2016         GeoVax Applauds Passage of Senate Bill to Accelerate Development of Zika Virus Vaccines
February, 2016     GeoVax to Develop Vaccine Against Zika Virus

Long Speculation on GOVX's Zika Vaccine:

On November 6, 2016, 60 Minutes did a segment titled: The Zika Virus. The pieced highlighted a Zika vaccine platform that appears to be proving successful. The platform described is similar to that of GOVX' s Intellectual Property. Other connections include a CDC sponsorship & Emory University. No definitive evidence has been disclosed. 



Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GOVX News: Current Report Filing (8-k) 08/14/2018 04:38:47 PM
GOVX News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 08/07/2018 04:44:34 PM
GOVX News: Quarterly Report (10-q) 08/07/2018 04:43:43 PM
GOVX News: Current Report Filing (8-k) 08/07/2018 03:17:28 PM
GOVX News: Current Report Filing (8-k) 06/15/2018 12:36:12 PM
News News Alert: Current Report Filing (8-k) 08/14/2018 04:38:47 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#5780   right, perpetual hell is a perfect word. Trompete 08/15/18 02:15:04 PM
#5779   Good News in: McNally retiring Myplace 08/14/18 10:01:56 AM
#5778   2 trials starting soon, AGT plus another company. Trompete 06/25/18 04:35:14 PM
#5777   Very strange indeed. Can't really understand someone who is dolse 06/24/18 06:00:17 PM
#5776   what are you talking about? I hold over Trompete 06/24/18 11:55:31 AM
#5775   Do your own DD people. dolse 06/24/18 11:51:52 AM
#5774   I think they resigned of HIV...Glaxo and Sanofi Trompete 06/24/18 11:32:05 AM
#5773   Yes, I agree with over 70% protection rate dolse 06/24/18 11:27:51 AM
#5772   Phase 3 of the trial, or they're doing Trompete 06/24/18 10:30:17 AM
#5771   What is this phase 3? If Geovax HIV vaccine dolse 06/24/18 10:28:27 AM
#5770   Yes, but there is no phase 3.. Financing Trompete 06/24/18 10:16:39 AM
#5769   HIV vaccine is most important in the world dolse 06/24/18 10:12:31 AM
#5768   It was till phase 2. There is no Trompete 06/24/18 06:45:04 AM
#5767   I know, I ment zika vaccine, which according Trompete 06/24/18 04:51:52 AM
#5766   Govax is in human trials in hiv vaccine. dolse 06/24/18 12:30:55 AM
#5765   The Geovax HIV vaccine is in clinical trials. FallujaDan 06/21/18 10:25:11 AM
#5764   It is strange, probably because the this all Trompete 06/19/18 02:19:21 PM
#5763   Wouldn't it be Funny, sad, and infuriating if Myplace 06/19/18 02:17:37 PM
#5762   I'm done with it, I guess...Holding so long Trompete 06/18/18 02:27:23 PM
#5761   Really like what we have here. Accumulating more Dasher95 06/18/18 02:15:00 PM
#5760   Someone sure thought something this am. 194k Myplace 06/15/18 05:39:10 PM
#5759   I hope this will skyrocket eventually... Hope, holding Trompete 06/15/18 11:44:53 AM
#5758   Seems to be a Fight to keep price down Myplace 06/15/18 10:28:19 AM
#5757   450k on the opening= wonder who bought and why jdlamont 06/15/18 09:36:03 AM
#5756   Correction 9am Myplace 06/14/18 09:38:43 AM
#5755   Thursday 6-14-18 2pm I believe. Myplace 06/13/18 09:04:19 PM
#5754 And nothing happe Trompete 06/12/18 02:05:48 PM
#5753   Well 8% Dilution , with No corresponding price Myplace 06/07/18 11:38:54 AM
#5752   curious when they test the ebola vaccine on Trompete 05/31/18 03:24:48 PM
#5751   volume picking up-1.5 mil already before noon. Interest jdlamont 05/31/18 12:31:58 PM
#5750   NIH seems committed to funding their research jdlamont 05/26/18 10:07:52 PM
#5749   unusual volume for this stock... Trompete 05/26/18 02:04:26 AM
#5748   McNally has been a disappointment since he arrived. Myplace 05/24/18 05:26:03 PM
#5747   Now Lassa and Zika funded in the last jdlamont 05/24/18 01:07:47 PM
#5746   that 500 mil to 1 billion is low gamblerjag 05/24/18 10:29:55 AM
#5745   Another good grant!!. Holder since 2008 and gamblerjag 05/24/18 10:28:43 AM
#5744   NIH grant for Zika. GeoVax Awarded NIH Grant for MufasaBreath 05/24/18 09:07:11 AM
#5743   agree, but lack of financing makes the trials Trompete 05/24/18 12:27:15 AM
#5742   I've been invested here off and on for somanymike 05/23/18 09:12:42 PM
#5741   yes, I think accumulation going on right now Trompete 05/23/18 01:48:45 PM
#5740   They are a great company with great people! wheely 05/23/18 10:31:28 AM
#5739   Little cash is a real problem. They should Trompete 05/23/18 10:12:45 AM
#5738   They have little cash. The will have to wheely 05/23/18 09:59:22 AM
#5737   What? Authorized shares don't matter, they only matter Trompete 05/23/18 09:51:12 AM
#5736   Look up the difference in authorized shares verse wheely 05/23/18 09:50:15 AM
#5735   What? They have approx 120m shs not 600mm... Trompete 05/23/18 09:44:19 AM
#5734   They have very little cash!!! The AS shares wheely 05/23/18 09:42:55 AM
#5733   the pipeline is great, we can agree on Trompete 05/21/18 04:01:45 PM
#5732   Market cap of not even 5 mio usd... Trompete 05/15/18 04:04:24 PM
#5731   new ebola outbreak jdlamont 05/11/18 02:19:26 PM